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Abstract
Aims/hypothesis Trials have not demonstrated benefits to the population of screening for type 2 diabetes. However, there may be
cost savings for those found to have diabetes. We therefore aimed to compare healthcare costs among individuals with incident
type 2 diabetes in a screened group with those in an unscreened group.
Methods In this register-based, non-randomised controlled trial, eligible individuals were men and women aged 40–69 years
without known diabetes who were registered with a general practice in Denmark (n = 1,912,392). Between 2001 and 2006,
153,107 individuals registered with 181 practices participating in the Anglo–Danish–Dutch Study of Intensive Treatment in
People with Screen Detected Diabetes in Primary Care (ADDITION)-Denmark study were sent a diabetes risk-score question-
naire. Individuals with a moderate-to-high risk were invited to visit their family doctor for assessment of diabetes status and
cardiovascular risk (screening group). The 1,759,285 individuals registered with all other practices in Denmark constituted the
retrospectively constructed no-screening (control) group. In this post hoc analysis, we identified individuals from the screening
and no-screening groups who were diagnosed with diabetes between 2001 and 2009 (n = 139,075). Using national registry data,
we quantified the cost of healthcare services in these two groups between 2001 and 2012. From a healthcare sector perspective,
we estimated the potential healthcare cost savings for individuals with diabetes that were attributable to the screening programme.
Results In the screening group, 27,177 of 153,107 individuals (18% of those sent a risk-score questionnaire) attended for
screening, 1533 of whom were diagnosed with diabetes. Between 2001 and 2009, 13,992 people were newly diagnosed with
diabetes in the screening group (including those diagnosed by screening) and 125,083 in the no-screening group. Healthcare costs
were significantly lower in the screening group compared with the no-screening group (difference inmean total annual healthcare
costs −€889 per individual with incident diabetes; 95% CI −€1196, −€581). The screening programme was associated with a cost
saving per person with incident diabetes over a 5-year period of €2688 (95% CI €1421, €3995).
Conclusions/interpretation Healthcare costs were lower among individuals with incident type 2 diabetes in the screened group
compared with the unscreened group. The relatively modest cost of screening per person discovered to have developed diabetes
was offset within 2 years by savings in the healthcare system.
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Introduction
Although modelling studies indicate that screening for type 2
diabetes might be effective and cost-effective [1–3], trials of
population-based screening for type 2 diabetes [4] and related
cardiovascular risk factors [5] have not demonstrated benefi-
cial effects at the population level. However, there appear to
be benefits for those found to have diabetes. We have previ-
ously shown that screening for type 2 diabetes and cardiovas-
cular risk factors does not reduce mortality and cardiovascular
disease (CVD) in the general population in Denmark [5], but
for individuals diagnosed with diabetes, screening was asso-
ciated with a reduction in mortality and risk of CVD [6].
Using data from Danish national registers and a retrospective-
ly constructed control group, we extended this analysis to
compare total healthcare costs for individuals with incident
diabetes in the screening and no-screening groups, and esti-
mated the potential cost savings of the Anglo–Danish–Dutch
Study of Intensive Treatment in People with Screen Detected
Diabetes in Primary Care (ADDITION) intervention from a
healthcare sector perspective.
Methods
ADDITION-Europe is a cluster-randomised trial comparing
the effects of screening for type 2 diabetes followed by inten-
sive treatment or routine care [7, 8]. We report here results from
a post hoc analysis using data from the screening phase of the
Danish arm of the study in conjunction with data from Danish
national registers. Ethical approval for the ADDITION-
Denmark study was granted by a local scientific committee
(number 20000183). As this was a registry-based study using
anonymised data, participants did not give informed consent.
This approach was approved by the Danish Data Protection
Agency and the Danish Health and Medicine Authority.
Screening programme Full details of the programme have
been reported elsewhere [5, 6, 9]. In brief, we performed a
population-based, stepwise screening programme in people
aged 40–69 years without known diabetes between 2001
and 2006 [7, 8, 10]. All general practices in five out of 16
counties in Denmark (Copenhagen, Aarhus, Ringkoebing,
Ribe and South Jutland; n = 744) were invited to take part in
ADDITION-Denmark; of these, 209 (28%) accepted.
Eligible individuals registered with the 181 practices that
agreed to take part were sent a diabetes risk-score question-
naire [8, 10], with an invitation to visit their general practition-
er (GP) for a diabetes test and a cardiovascular risk assessment
•
•
•
•
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if they scored ≥5 (maximum 15 points), or were invited when
visiting the practice for another reason (n = 35 practices). No
reminders were sent. Participants who attended a screening
appointment underwent measurement of height, weight and
blood pressure. A capillary blood sample was taken for testing
of random blood glucose. A venous blood sample was taken
for measurement of total cholesterol and HbA1c. GPs were
encouraged to calculate participants’ scores from European
Heart (Systematic COronary Risk Evaluation [SCORE]) [11]
charts during the appointment, inform participants about their
score and provide appropriate advice and treatment to those at
high risk. Individuals with a random blood glucose
≥5.5 mmol/l or HbA1c ≥39.9 mmol/mol (5.8%) were invited
to return to the practice for a fasting blood glucose capillary
test. An OGTTwas performed at the same consultation if the
fasting blood glucose was 5.6–6.1 mmol/l and/or the HbA1c ≥
39.9 mmol/mol (5.8%). WHO 1999 criteria were used to di-
agnose diabetes [12].
In the intervention group, participants diagnosed with type
2 diabetes were subsequently managed according to the treat-
ment regimens to which their practice was allocated: routine
care or intensive treatment [9]. Intensive treatment included:
small group or practice-based educational meetings with GPs
and nurses to discuss treatment targets, algorithms and life-
style advice; audit and feedback in group meetings up to twice
per year or coordinated by post; and patient education mate-
rials. GPs underwent a 1.5 day educational seminar to train in
motivational interviewing to encourage lifestyle change.
Sampling frame We identified all eligible individuals in the
original ADDITION-Denmark study (n = 153,107), including
those who did not attend for screening, in the Danish National
Diabetes Register [13] (the screening group). Using the same
registry, we also identified all individuals aged 40–69 years
without known diabetes who, between 2001 and 2006, were
registered with general practices that were not invited to take
part in ADDITION-Denmark or who declined to take part in
ADDITION-Denmark (n = 1,759,285) (the no-screening con-
trol group). We then identified individuals from the screening
and no-screening groups who were diagnosed with incident
diabetes between 1 January 2001 and 31 December 2009 (Fig.
1). We included individuals diagnosed with diabetes during
this period based on recent estimates of lead time, which sug-
gest that around 2.2 years elapses between detection by
screening and clinical diagnosis [6]. Including individuals di-
agnosed with diabetes in the 3 years (2006–2009) after the end
of the ADDITION screening phase (2001–2006) would there-
fore capture most individuals in the no-screening group who
could have been diagnosed by screening if they had been in
the screening group. Our definition of incident diabetes for
both groups was a proxy measure based on date of inclusion
in the Danish National Diabetes Register [14].
DataWe linked information about individuals diagnosed with
diabetes to other Danish registers using unique civil registra-
tion numbers. We retrieved information on age, sex, educa-
tion, immigration/emigration, citizenship, redeemed
cardioprotective medication and chronic disease. Education
was categorised according to UNESCO’s International
Standard Classification of Education [15]. We grouped data
on citizenship into European and non-European as a proxy for
ethnicity. Data on healthcare service usage in primary and
secondary care, as well as information on redeemed medica-
tion, were retrieved from the National Patient Register, the
National Health Insurance Register and the National
Prescription Register [16].
All men and women aged 40–69 years without known diabetes in Denmark in 
2001; n=1,912,392
1,759,285 individuals registered at 2247 
practices not taking part in
screening
Screen detection: 1350
Clinical detection: 12,642
Screen detection: 0
Clinical detection: 125,083
2001
2012
2006
2009
Followed up for mortality and incident CVD outcomes until 31 December 2012
153,107 individuals registered at 
181 practices taking part in 
screening (2001 to 2006)
Screening
period
Fig. 1 Visual representation of
the sampling frame. The ‘S’ in a
blue circle denotes individuals
detected by the ADDITION
stepwise screening programme.
The ‘C’ in a red circle denotes
individuals with clinically
diagnosed diabetes. Reproduced
from Simmons et al. [6] under the
terms of the CC BY 4.0
Attribution License (http://
creativecommons.org/licenses/
by/4.0/)
1308 Diabetologia (2018) 61:1306–1314
Costs
The costs of ADDITION-Denmark include the cost of the
screening programme and the cost of the intensive treatment
programme (for those found with screen-detected diabetes
who were randomised to this arm). Healthcare costs include
total costs of healthcare service usage and redeemed medica-
tion for all individuals in our sampling frame during the
follow-up period. All costs were calculated in Danish krone
(DKK) and converted to Euros (conversion rate €1 = 7.44
DKK), and were from a healthcare sector perspective; for
example, all costs, included overhead costs and participants’
own payment for redeemed medication.
The cost of the screening programme has previously
been reported [17]. The average cost of detecting an indi-
vidual with previously undiagnosed type 2 diabetes was
estimated by Dalsgaard and colleagues in 2010 to be
€936 [17], including the cost of sending the invitation let-
ter, and the cost of the screening consultations and labora-
tory tests. We multiplied GP fees by 1.438 to capture over-
head costs, as Danish GPs are paid on a combined capita-
tion and fee-for-service scheme.
The cost of the intensive treatment intervention includes:
the cost of small group or practice-based educational meetings
with GPs and nurses to discuss treatment targets, algorithms
and lifestyle advice; audit and feedback in group meetings up
to twice per year or coordinated by post; patient education
materials; and small financial incentives for GPs [9]. In addi-
tion, 64 GPs participated in a 1.5 day educational seminar on
motivational interviewing. Summing the costs of the screen-
ing programme and the intensive treatment costs provided an
estimate of €967 per individual with incident diabetes.
The cost of healthcare usage was defined as opportunity
costs using market values (excluding value-added tax [VAT])
[18, 19]. We quantified the healthcare costs in the screening
and no-screening groups using individual-level register data.
These data allowed us to estimate the cost of: (1) inpatient
healthcare utilisation (data available for 2007–2012); (2) out-
patient healthcare utilisation (data available for 2007–2012);
(3) primary care utilisation (data available for 2001–2012);
and (4) redeemed medications (data available for 2001–
2012). Table 1 describes the different cost units and our
methods for calculating them.
Statistical analysis We summarised characteristics of all indi-
viduals diagnosed with incident diabetes between 2001 and
2009 separately in the screening and no-screening groups.
Date of entry to the study was the date of inclusion in the
diabetes register. All analyses were completed using Stata
version 14.1 (Stata, College Station, TX, USA). Statistical
significance was inferred at a two-tailed p < 0.05. We calcu-
lated robust standard errors to allow for clustering of partici-
pants within practices.
Cost analysis We quantified healthcare usage and calculated
average healthcare costs in each group over the follow-up
period by dividing the total healthcare costs for each individ-
ual by the time they spent in the study. As data from the health
registers were available for different time periods, we conduct-
ed analyses for two time periods: 2001–2012 (with an average
of 7.0 years follow-up; n = 139,048) and 2007–2012 (with an
average of 5.2 years follow-up; n = 133,307). In this second
analysis, we only included individuals who were alive and
living in Denmark on 1 January 2007.
To examine potential differences in healthcare costs be-
tween the groups, we used ordinary least squares regression,
adjusting for age, sex, education and GP county. We also
controlled for prevalent chronic disease at diagnosis (ischae-
mic heart disease [IHD], stroke and cancer). We quantified
costs from more than 3 years before diagnosis to more than
6 years after diagnosis using difference-in-difference regres-
sion on panel data (data covering more years over a time
period) with mean correction for confounders. The
difference-in-difference method allowed us to estimate
the ‘isolated’ effect of the ADDITION intervention on
healthcare costs by examining the differences between
the screening group and the no-screening group within
the periods before and after diagnosis. We included
mean-adjusted covariates in the regression, for which we
applied effect coding for the categorical variables [20] in
order to adjust for the demographic, epidemiological and
regional differences. We were therefore able to interpret
the constant term as the predicted healthcare costs for an
individual in the no-screening group in the year of
diagnosis.
To estimate the potential economic benefits of the screen-
ing programme among individuals with incident diabetes, we
subtracted the cost of the screening programme from the esti-
mated healthcare cost savings accruing in the screening group.
We calculated cost savings over a 5 year period after the
screening phase using an annual discount rate of 5%.
Sensitivity analysis We also examined the difference in
healthcare costs between the screening group assigned to rou-
tine care only and the no-screening group.
Results
Population characteristics Of 153,107 eligible people in the
screening group who were sent a diabetes risk-score question-
naire, 27,177 (18%) attended their GP for a diabetes test and a
cardiovascular risk assessment. A total of 1533 participants
(1% of those eligible for screening) were diagnosed with dia-
betes; 1406 of these were subsequently included in the diabe-
tes register. There were 1,759,285 individuals in the
no-screening group.
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Between 1 January 2001 and 31 December 2009, 139,075
people from our sampling frame were diagnosed with incident
diabetes and included in the Danish National Diabetes
Register. Of these, 13,992 (10%) were in the screening group,
and 125,083 (90%) in the no-screening group. The groups
were well balanced for age and citizenship (Table 2). There
were slightly fewer men in the screening group (54%) than the
no-screening group (56%). A larger proportion of the screen-
ing group had received over 15 years of education. Slightly
lower proportions of the screening group had experienced
IHD, stroke or cancer before the diagnosis of diabetes com-
pared with the no-screening group.
Healthcare costs in the screening and no-screening groups
Figures 2, 3, 4, 5 show the mean-adjusted annual costs per
participant with incident diabetes by healthcare sector both
before and after the time of diagnosis in the screening and
n o - s c r e e n i n g g r o u p s . T h e r e s u l t s f r om t h e
difference-in-difference regression analyses are presented in
electronic supplementary material [ESM] Table 1.
After diagnosis, healthcare usage and subsequent costs
were significantly higher in the no-screening group than the
screening group. For example, primary care costs were ap-
proximately 5% higher in the no-screening group than the
screening group during follow-up. The costs of redeemed
medication were already higher in the no-screening group
before diagnosis, but the difference between the groups in-
creased further after diabetes diagnosis. Costs were approxi-
mately 12% higher in the no-screening group compared with
the screening group in the 6 years following diagnosis. For
Table 1 Cost units and methods
of calculation for cost
components
Cost component Cost unit and method of calculation
Inpatient and outpatient services delivered in Danish
hospitals registered in the National Hospital
Register
DRG tariffs and the DAGS were applied [28].
Costs are understood as opportunity costs, i.e.
resources are scarce and resources spent in one area
cannot be spent in another [18]. Activities in the
Danish healthcare sector have been converted into a
monetary cost through the use of the DRG system. The
DRG tariffs are calculated from average operating
costs within each DRG group on a nationwide level
[28]. The system is developed for settlement of
accounts for patients in hospitals, individuals who
have chosen a hospital in another region than their
region of residence and patients in private hospitals.
This calculation produces approximate average costs,
which should be used with caution in economic
evaluations [29]
Primary care services delivered by GPs and privately
practising specialists
Visits by GPs, physiotherapists, chiropractors,
chiropodists, opticians and dietitians
Reimbursement fees between the National Health
Insurance scheme and privately practising physicians
are used as cost units. GPs are compensated by regions
through a combination of a per capita fee
(approximately 30% of the total) and a fee-for-service
(approximately 70%) [30]. To reflect this payment
scheme in the unit cost, 43.8% of the fee-for-service in
general practice was added to the cost. Overhead costs
covered by the capitation fee were distributed by
resource burden (and not across the number of visits)
Prescribed pharmaceuticals dispensed by Danish
pharmacies and registered in DNPrR.
(Pharmaceuticals consumed in hospitals are
included in DRG tariffs. Over-the-counter drugs are
not included in this analysis)
Total sales price includes individuals’ out-of-pocket
payments. Costs of prescribed pharmaceuticals are
shared between the individual and the primary
healthcare sector by a co-payment scheme in Denmark
in which individuals are reimbursed according to their
need. These costs were aggregated since total costs are
measured regardless of who pays. Although
pharmaceutical consumption includes VAT, Danish
healthcare services are exempted fromVAT. As VAT is
25% in Denmark, 20% of pharmaceutical
consumption was subtracted to calculate comparable
net costs
DAGS, Danish Ambulatory Grouping System; DRG, diagnosis related grouping; DNPrR, Danish National
Prescription Registry
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inpatient and outpatient visits, there were no clear trends as-
sociated with the point of diabetes diagnosis. On average,
however costs were lower among the screening group com-
pared with the no-screening group both prior to and following
diagnosis.
The mean annual cost estimates for primary care and
redeemed medication were based on 2001–2012 data, while
inpatient and outpatient costs were based on 2007–2012 data.
The mean total cost difference is therefore estimated as the
sum of the four mean annual cost components: inpatient and
outpatient costs, primary care cost and cost of redeemed med-
ication. After adjustment for confounders, annual healthcare
costs per individual with incident diabetes were significantly
lower in the screening group than the no-screening group
across all healthcare sectors and for redeemed medication:
annual difference in inpatient care costs −€662 (95% CI
−€865, −€459), outpatient care costs −€82 (95% CI −€157,
−€7), primary care costs −€51, (95% CI −€63, −€38) and
pharmaceuticals −€94 (95% CI −€111, −€76). The difference
in mean total annual healthcare costs per individual with inci-
dent diabetes between groups was −€889 (95% CI −€1196,
−€581).
After subtract ing the cost of introducing the
ADDITION screening programme (€967 per participant
with incident diabetes) from the estimated annual
healthcare cost savings (€889 per participant with incident
diabetes), and discounting this figure in the 5 years fol-
lowing the intervention, there was a cost saving associated
with each individual with incident diabetes over a 5 year
period of €2688 (95% CI €1421, €3995). This finding
suggests that the intervention was associated with cost
Table 2 Characteristics of individuals with diabetes by screening group
Variable Screening group
(N=13,992)
No-screening (control)
group (N=125,083)
Mean age at diagnosis 59.9 ± 7.7 59.2 ± 9.2
Male sex 7495 (53.6) 70552 (56.4)
Years of education
0–10 5610 (40.1) 55,765 (44.6)
10–15 6237 (44.6) 55,226 (44.2)
>15 2145 (15.3) 14,082 (11.3)
European citizenship 13,944 (99.7) 123,849 (99)
Previous IHDa 1586 (11.3) 16,216 (13)
Previous strokea 628 (4.5) 6851 (5.5)
Previous cancera 2027 (14.5) 19,276 (15.4)
Data are mean ± SD or n (%)
a Data taken from the National Patient Registry; data were included from
1994 until the date of diabetes diagnosis
Time from diabetes diagnosis (years)
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Fig. 3 Primary care costs per participant with incident diabetes 2001–
2012 by intervention group according to time from diagnosis. Dotted line,
costs for the no-screening (control) group; solid line, costs for the screen-
ing group. Black circles indicate that estimated mean differences in costs
between the no-screening and screening groups in each time period are
significantly different from zero (p<0.05)
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Fig. 2 Pharmaceutical costs per participant with incident diabetes 2001–
2012 by intervention group according to time from diagnosis. Dotted line,
costs for the no-screening (control) group; solid line, costs for the screen-
ing group. Black circles indicate that estimated mean differences in costs
between the no-screening and screening groups in each time period are
significantly different from zero (p<0.05)
0
2000
4000
6000
8000
10,000
12,000
14,000
-2 -1 0 1 2 3 4 5 ≥6
Time from diabetes diagnosis (years)
M
ea
n 
an
nu
al
 c
os
ts
 p
er
 in
di
vi
du
al
 (
€
)
Fig. 4 Inpatient care costs per participant with incident diabetes 2007–
2012 by intervention group according to time from diagnosis. Dotted line,
costs for the no-screening (control) group; solid line, costs for the screen-
ing group. Black circles, estimated mean differences in costs between the
no-screening and screening groups in each time period are significantly
different from zero (p<0.05); white circles, there are no statistically sig-
nificant estimated mean differences in costs in each time period (p≥0.05)
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Discussion
Our cost analysis of the ADDITION-Denmark screening
programme showed that healthcare costs were significantly
lower for individuals with incident type 2 diabetes in the
screening group compared with the no-screening group.
This was true for all examined health services—inpatient,
outpatient and primary care—as well as for medication
costs. We also showed that within 2 years of being
Time from diabetes diagnosis (years)
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Fig. 5 Outpatient care costs per participant with incident diabetes 2007–
2012 by intervention group according to time from diagnosis. Dotted line,
costs for the no-screening (control) group; solid line, costs for the screen-
ing group. Black circles, estimated mean differences in costs between the
no-screening and screening groups in each time period are significantly
different from zero (p<0.05); white circles, there are no statistically sig-
nificant estimated mean differences in costs in each time period (p≥0.05)
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savings in the healthcare system within 2 years of the
screening programme being introduced. Based on the
13,992 individuals with diabetes in the screening group,
we estimate that the intervention saved the Danish
healthcare system almost €37.6 million (95% CI €19.8
million, €55.3 million) in the 5 years after the introduc-
tion of the screening programme.
Sensitivity analysis In our sensitivity analysis, the annual
healthcare costs of the screening population assigned to rou-
tine care remained lower than costs in the no-screening group
for: inpatient care −€633 (95% CI −€898, −€368), primary
care −€41 (95% CI −€58, −€24) and medication −€90 (95%
CI −€117, −€63). The outpatient care costs were similar in
both groups. As the costs of the screening programme within
the routine care group were €936 per individual, and the total
mean annual difference in costs between the screening and
no-screening groups was −€752 (95% CI −€1,169, −€335)
per individual, ADDITION brings cost savings of €2158
(95%CI €444; €3871) per individual within 5 years following
the screening period. For the whole population of 13,992 in-
dividuals, the cost savings would be €30.1 million (95% CI
€6.2 million, €54.1 million).
introduced, ADDITION-Denmark was associated with
cost savings in the healthcare system.
Our estimates of annual healthcare costs for individuals
with diabetes in Denmark align well with the published liter-
ature. For example, a previous study [21] showed that the cost
per individual with diabetes per year was €6390 in 2011 (com-
pared with an annual mean of €5910 for the screening group
and €6854 for the no-screening group between 2007 and
2012).
In ADDITION-Denmark, the relatively modest cost of
screening per participant discovered to have diabetes was off-
set within 2 years by savings in the healthcare system. In terms
of comparison, there are no other published trials that examine
the costs of healthcare among individuals with incident type 2
diabetes in a screened group with those in an unscreened
group. However, modelling studies show that screening for
type 2 diabetes at the population level would be
cost-effective over 30 and 50 years [1, 2, 22].
Herman et al argue that that the benefits of screening and
treatment primarily accrue from early diagnosis and by has-
tening the treatment of CVD risk factors during the lead
t im e [ 3 ] . We h a v e p r e v i o u s l y r e p o r t e d t h a t
ADDITION-Denmark brought forward the diagnosis of di-
abetes by 2.1 years and was associated with a significant
reduction in mortality and CVD among those with diabetes
[5]. We observed an increase in the proportion of
screen-detected individuals who redeemed cardioprotective
medication during follow-up [6]. However, larger propor-
tions of clinically diagnosed individuals in the no-screening
group redeemed medication compared with clinically diag-
nosed individuals in the screening group. As individuals in
the no-screening group were diagnosed at a later stage in
the disease trajectory, they may have had higher cholester-
ol, blood glucose and blood pressure values at diagnosis
compared with the screening group, necessitating higher
levels (and costs) of cardioprotective medication. The pro-
motion of healthy behaviour change may also have impact-
ed on CVD risk factors and CVD and mortality rates, and
consequently lowered costs of healthcare among partici-
pants with diabetes in the screening group.
New drugs are more expensive, which might increase
the costs based on these study data. However, new agents
tend to be restricted to second- and third-line treatment,
and hence may not have a major impact on our estimates
of cost savings associated with screening in the first 5–
10 years of the disease trajectory. In addition, preventive
strategies for diabetes have gained traction in the past
decade and may be associated with further cost savings.
For example, the Diabetes Prevention Program in the
USA [22] is being implemented through a number of dif-
ferent delivery channels [23, 24], and NHS England
launched a National Diabetes Prevention Programme in
2016, which now covers 75% of the English population
[25, 26]. Modelling studies suggest that these programmes
will be cost-effective in the long term.
Strengths and limitations In this study, we used real-world,
individual participant-level data to examine healthcare costs
among participants with incident type 2 diabetes in a screened
group compared with an unscreened group. We applied a
healthcare sector perspective in our cost analysis. Only costs
related to healthcare services and redeemed medication were
included in the study. As such, costs relating to individuals’
lost labour market productivity and utilisation of nursing ser-
vices or other services such as transportation and helping aids
in the house were not included in our analysis. These costs
have previously been demonstrated to be high among people
with diabetes, making up as much as 80% of the total societal
costs [21, 23]. Furthermore, we did not include quality of life
or the value of higher life expectancy in our analyses. Data on
quality of life would enable a better comparison with the lit-
erature on the cost-utility of screening and prevention [22,
24–27].
We also did not include the healthcare cost savings accru-
ing from an individual’s death, as it will always be less expen-
sive if a person dies and hence there is no argument for treat-
ment or prevention [18].
A limitation of our study was the non-randomised de-
sign, as we cannot eliminate the possibility of selection bias
and residual confounding. Groups were well balanced for
the characteristics investigated at baseline. However, our
findings might have been influenced by the higher levels
of education and the slightly lower levels of pre-existing
chronic disease in the intervention group. The cost of
redeemed medication was also lower in the screening group
before the introduction of the ADDITION-Denmark
screening intervention. We adjusted for age, sex, education,
GP county and prevalent chronic disease at diagnosis,
which impacted on the size of the cost difference, although
the final result remained significant. It is likely that
adjusting for county took account of some of the potential
socioeconomic differences across different regions in
Denmark. We tried to minimize lead- and length-time
biases by comparing costs for all individuals diagnosed
with diabetes in the screening and no-screening groups.
We could have applied bootstrapping and cost acceptability
curves to handle uncertainty [18]. As the intervention proved
to be cost-saving within a short time period, we chose instead
to use the lowest CI levels to describe uncertainty.
ConclusionsHealthcare costs were lower among individuals
with incident type 2 diabetes in a screened group compared
with an unscreened group. The relatively modest cost of
screening per participant discovered to have developed di-
abetes was offset within 2 years by savings in the
healthcare system.
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